Current standard and trends in oesophageal cancer

European Journal of Cancer

Volumn 47, Issue SUPPL. 3, 2011, Pages

  Lordick, Florian ^a  

^a KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FLUORODEOXYGLUCOSE F 18; TRASTUZUMAB;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CHEMORADIOTHERAPY; ESOPHAGUS CANCER; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; REFERENCE STANDARDS; STANDARD OF CARE;

EID: 80053245922     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/S0959-8049(11)70200-3     Document Type: Article

References (10)

1. F Kamangar, GM Dores, WE Anderson Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2006 2137 2150 (Pubitemid 46655601)
2. F Lordick, HJ Stein, C Peschel, JR Siewert Neoadjuvant therapy in oesophago-gastric cancer Br J Surg 91 2004 540 551
3. V Gebski, B Burmeister, BM Smithers, K Foo, J Zalcberg, J Simes, Australasian Gastro-Intestinal Trials Group Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis Lancet Oncol 8 2007 226 234 (Pubitemid 46291702)
4. M Stahl, J Oliveira Esophageal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl 4 2009 iv32 iv33
5. M Stahl, M Stuschke, N Lehmann et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus J Clin Oncol 23 2005 2310 2317 (Pubitemid 46218723)
6. F Lordick, K Ott, BJ Krause et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial Lancet Oncol 8 2007 797 805 (Pubitemid 47308659)
7. F Lordick, T Ruers, DE Aust European Organisation of Research and Treatment of Cancer Gastrointestinal Group European Organisation of Research and Treatment of Cancer(EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer Eur J Cancer 44 2008 1807 1819
8. S Lorenzen, T Schuster, R Porschen et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie Ann Oncol 20 2009 1667 1673
9. F Lordick, B Luber, S Lorenzen et al. Cetuximab plus oxaliplatin/ leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Br J Cancer 102 2010 500 505
10. YJ Bang, E Van Cutsem, A Feyereislova for the ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697